FINWIRES · TerminalLIVE
FINWIRES

SHE:300347

8 stories mentioning SHE:300347Updated 7d ago

Every FINWIRES story that references SHE:300347, newest first.

What are analysts saying about SHE:300347?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on SHE:300347?

Asia

Hangzhou Tigermed Consulting Shareholders Face Fine for Late Disclosures

Hangzhou Tigermed Consulting (SHE:300347) controlling shareholders Ye Xiaoping and Cao Xiaochun face combined fines of up to 1 million yuan for late disclosures of share reductions, according to a Saturday filing with the Shenzhen bourse.The two shareholders failed to submit equity change reports in 2019 on time, retroactively submitting the disclosure on May 12, 2026. The tandem also failed to disclose on time a stake reduction in 2022, only disclosing the matter in May.

SHE:300347
Asia

Tigermed Controlling Shareholders Face Fines Over Disclosure Violations

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) said two directors and controlling shareholders face proposed fines of 500,000 yuan each over historical shareholding disclosure violations, according to a Sept. 11 Hong Kong bourse filing.Ye Xiaoping and Cao Xiaochun received warning letters and advance notices of administrative penalties from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission.The regulator said the pair failed to timely disclose changes in their combined A-share holdings that reached 5% in September 2019 and a subsequent 1% reduction in December 2022.

HKG:3347SHE:300347
Asia

Jefferies Adjusts Hangzhou Tigermed Consulting's Price Target to 55 Yuan From 65 Yuan, Keeps at Hold

Hangzhou Tigermed Consulting (SHE:300347) has an average rating of overweight and mean price target of 56.11 yuan, according to analysts polled by FactSet.

SHE:300347
Asia

Tigermed Consulting Swings to H1 Attributable Loss; Revenue Up

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) reported 413.2 million yuan in loss attributable to owners for the first half, compared with an attributable profit of 383.3 million yuan a year ago, a Friday bourse filing showed.Loss per share for the period was 0.48 yuan, whereas the company had made earnings per share of 0.45 yuan in the prior-year period.For the six months ended June 30, operating revenue was 3.71 billion yuan, versus 3.25 billion yuan previously, the Chinese medical laboratory operator said.

HKG:3347SHE:300347
Asia

Hangzhou Tigermed Indirect Unit Eyes 10 Million Yuan Credit Facility

Hangzhou Tigermed Consulting's (SHE:300347) indirect unit Frontage Suzhou plans to apply for a credit facility with Minsheng Bank of up to 10 million yuan to cover its daily business development needs.Holding subsidiary Frontage Shanghai agreed to provide a joint liability guarantee for up to the full amount, according to a Tuesday filing with the Shenzhen bourse.Shares of the medical laboratory operator were up 2% in recent trade.

SHE:300347
Asia

Tigermed Consulting to Pay 2025 Dividend on July 31

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) will pay a dividend of around HK$1.45 per 10 shares for the year 2025, according to a Tuesday Hong Kong bourse filing.Shares of the Chinese medical laboratory operator were down nearly 2% in Wednesday afternoon trading.The dividend will be paid July 31 to shareholders of record June 26.

HKG:3347SHE:300347
Asia

Hangzhou Tigermed Consulting Names New Chairman, CFO

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) elected Ye Xiaoping as chairman and appointed Yang Chengcheng as chief financial officer, effective Tuesday, according to a same-day Hong Kong bourse filing.The clinical trial services provider also appointed Peng Yifei as chief operating officer and Wu Hao as co-president.

HKG:3347SHE:300347
Asia

Tigermed Consulting's Q1 Profit Slides 70%

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) recorded a 70% decline in attributable profit in the first quarter of 2026 to 49 million yuan from 165.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Earnings per share slipped to 0.06 yuan from 0.19 yuan in the corresponding period of the previous fiscal year.The medical laboratory company's revenue jumped 15% to 1.8 billion yuan from 1.56 billion yuan in the year-ago period.

HKG:3347SHE:300347

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:300347 in your portfolio
WheelAI
WheelAI
Analyze SHE:300347 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:300347